Best in Biotech 19 Nov 2024 Six bispecific antibody companies you should know about Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients. November 19, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 1 Nov 2024The immunometabolism landscape To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty. November 1, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 31 Oct 2024 Five T cell engager companies you should know about Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off. October 31, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2024 Six biotech companies advancing multiple sclerosis therapies Take a look at six multiple sclerosis companies trying to make a difference to patients by advancing new treatments for the CNS disease. October 24, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development. September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 3 Sep 2024 The crucial role of GS-CHO innovation in biopharmaceutical progress Learn how GS-CHO systems are advancing to improve yields and quality in biomanufacturing, meeting the rising need for effective therapeutic proteins. September 3, 2024 - 8 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt. August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? Discover why the immunology and inflammation market has recently been attracting a major wave of investment. July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 24 May 2024How biotech is tackling myasthenia gravis To talk about the disease, how it is being treated, and what is in the pipeline for future treatments, we had a conversation with Dana Vigier, head of Central Eastern and Northern Europe at Alexion. May 24, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 9 May 2024 BTK inhibitors: can these drugs tackle cancer and autoimmunity? BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases. May 9, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Apr 2024 Eight biotechnology companies leading the charge in Poland Discover eight biotech companies at the forefront of Poland’s emerging biotech sector, which is becoming a hotspot for startups. April 23, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 27 Mar 2024 Are new treatments for multiple sclerosis on the horizon? As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise. March 27, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email